Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma

Objective: The mainstay treatment of esophageal squamous cell carcinoma (ESCC) involves chemotherapy and immunotherapy. However, alternative therapies are required for patients who are refractory or intolerant to existing therapies. Methods: In this single-arm, multicenter, open-label phase Ib study...

Full description

Bibliographic Details
Main Authors: Ming Bai, Meng Wang, Ting Deng, Yuxian Bai, Kai Zang, Zhanhui Miao, Wenlin Gai, Liangzhi Xie, Yi Ba
Format: Article
Language:English
Published: China Anti-Cancer Association 2022-03-01
Series:Cancer Biology & Medicine
Subjects:
epidermal growth factor receptor
esophageal squamous cell carcinoma
sct200
monoclonal antibody
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/2010

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/2010

Similar Items